Workweek October 17, 2023
Blake Madden

Healthcare Headlines

GLP-1 Kidney Study News takes down Dialysis Names

  • Novo Nordisk’s GLP-1 trial was testing whether the widely used diabetes drug, which contains the active ingredient semaglutide, could delay progression of chronic kidney disease and lower the risk of death from kidney and heart problems.
  • The clinical trial was halted early because it was clear that the treatment would work for the designated population
  • Consequently, dialysis stocks – and other healthcare services names – tanked after news on Novo Nordisk’s kidney trial involving Semaglutide hit the wire. DaVita, Fresenius, and Outset Medical stocks were down double digits on the week. DaVita even issued a statement on the matter.
  • The potential clinical indications for GLP-1s are insane, and they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Medicare Advantage, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
National Pharmacists Day: Drug Topics’ Pharmacist Interviews from the Past Year
Personalized Medicine in GI Cancer: Transforming Treatment With Technology, Lifestyle Insights
STAT+: Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’
Our Sleep, Brain Aging, and Waste Clearance
Tune raises $175M for hepatitis B medicine, epigenetic research

Share This Article